{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:06:58Z","timestamp":1780927618414,"version":"3.54.1"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Inherited bone marrow failure syndromes (IBMFs) are a molecularly heterogeneous group of genetically-determined syndromes with a wide spectrum of clinical abnormalities and risk of hematopoietic neoplasia and reduced life expectancy. The prevalence is not well established but is growing due to the advent of genetic diagnostics. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative modality in eligible IBMF patients but the indications are individualized due to significant transplant-related morbidity, including secondary cancer. HSCT indications and practices are also impacted by the gradual introduction of gene therapies for IBMFs, but that remains developmental at the moment. Medical non-transplant therapies have played an important role in several IBMFs for decades. Their impact vary from nearly curative treatment in Diamond\u2013Blackfan Anemia (DBA), through supportive interventions, to experimental treatment aimed at impacting the natural course of the disease. This may be subject to change, because of the description of new syndromes or new pathomechanisms of the established syndromes. While their impact might be diminishing due the progress in gene therapy, there might be some new clinically useful interventions due to new medical technologies and the progress in drug-repurposing. The medical therapies can be used as a mainstay of therapy, bridge therapy to transplantation, peri- or post-transplantation aiming at amelioration of the hematological and non-hematological phenotype, improved growth and development, diminishing the risk of myeloid neoplasm or other cancer. Disease- and therapy-specific risks of these interventions must be actively addressed in patients. We present state-of-the-art and developmental applications of non-cellular therapies in IBMFs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1773574","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:58:58Z","timestamp":1772607538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Established and emerging non-cellular therapies in inherited bone marrow failure syndromes"],"prefix":"10.3389","volume":"17","author":[{"given":"Szymon","family":"Janczar","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Urba\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ussowicz","sequence":"additional","affiliation":[{"name":"Department of Paediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Mlynarski","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oncology and Hematology, Medical University of Lodz","place":["Lodz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1976634","article-title":"Chronic neutropenia: how best to assess severity and approach management","volume":"14","author":"Donadieu","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1749-6632.2011.06349.x","article-title":"Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome","volume":"1242","author":"Dror","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/asheducation-2017.1.96","article-title":"Treatment of inherited bone marrow failure syndromes beyond transplantation","volume":"2017","author":"Calado","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27724","article-title":"Long-term outcome of fanconi anemia patients from the italian registry on behalf of the marrow failure study group of the AIEOP (Italian association for pediatric haematology-oncology)","volume":"100","author":"Ricci","year":"2025","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10689-021-00263-z","article-title":"Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological Malignancies","volume":"20","author":"Schlegelberger","year":"2021","journal-title":"Fam Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1179\/1024533215Z.000000000381","article-title":"Inherited bone marrow failure syndromes","volume":"20","author":"Collins","year":"2015","journal-title":"Hematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006481","article-title":"Inherited bone marrow failure in the pediatric patient","volume":"140","author":"Dokal","year":"2022","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-781799","article-title":"Inherited bone marrow failure syndromes: considerations pre- and posttransplant","volume":"130","author":"Alter","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000095","article-title":"Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic Malignancy predisposition syndromes","volume":"2020","author":"Bonfim","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30206-6","article-title":"Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study","volume":"7","author":"Myers","year":"2020","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000393","article-title":"Modern management of Fanconi anemia","volume":"2022","author":"Dufour","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-023-02082-w","article-title":"Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia","volume":"38","author":"Liu","year":"2024","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01511-6","article-title":"Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9\/SAMD9L syndromes","volume":"27","author":"Sahoo","year":"2021","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.265124","article-title":"The arrival of personalized genomics in bone marrow failure","volume":"106","author":"Wlodarski","year":"2021","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0807057106","article-title":"Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia","volume":"106","author":"Calado","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01374-y","article-title":"Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome","volume":"56","author":"Bortnick","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1876393","article-title":"Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts","volume":"26","author":"Lu","year":"2021","journal-title":"Hematology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101132","DOI":"10.1016\/j.blre.2023.101132","article-title":"Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data","volume":"62","author":"Bosi","year":"2023","journal-title":"Blood Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16997","article-title":"Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita","volume":"193","author":"Kirschner","year":"2021","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16445","article-title":"Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry","volume":"189","author":"Catal\u00e0","year":"2020","journal-title":"Br J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225371","article-title":"Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases","volume":"83","author":"Eiers","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132284","article-title":"Steroid resistance in Diamond Blackfan anemia associates with p57Kip2 dysregulation in erythroid progenitors","volume":"130","author":"Ashley","year":"2020","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00063-2","article-title":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement","volume":"11","author":"Wlodarski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13632","article-title":"Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia","volume":"171","author":"Sj\u00f6gren","year":"2015","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281808","article-title":"Effects of nandrolone decanoate on telomere length and clinical outcome in patients with telomeropathies: a prospective trial","volume":"108","author":"Cl\u00e9","year":"2023","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282935","article-title":"Current use of androgens in bone marrow failure disorders: a report from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"109","author":"Pagliuca","year":"2024","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197196","article-title":"Comparable effects of the androgen derivatives danazol, oxymetholone and nandrolone on telomerase activity in human primary hematopoietic cells from patients with dyskeratosis congenita","volume":"21","author":"Vieri","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.1016\/j.beha.2021.101282","article-title":"Treatment of telomeropathies","volume":"34","author":"Vieri","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283564","article-title":"Bone marrow failure on steroids: when to use androgens","volume":"109","author":"Calado","year":"2024","journal-title":"Haematologica"},{"key":"B31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13023-019-1046-0","article-title":"Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes","volume":"14","author":"Arias-Salgado","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B32","volume-title":"Fanconi anemia clinical care guidelines.: fanconi anemia research fund","author":"Sroka","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/nyas.14248","article-title":"Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies","volume":"1466","author":"Ferreira","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S299591","article-title":"A review of romiplostim mechanism of action and clinical applicability","volume":"15","author":"Bussel","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19777","article-title":"What is the best second-line treatment for immune thrombocytopenia","volume":"205","author":"Mah\u00e9vas","year":"2024","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stem.2012.10.012","article-title":"Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage","volume":"12","author":"de Laval","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-515874","article-title":"Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF-\u03baB pathways and their target, IEX-1","volume":"123","author":"de Laval","year":"2014","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2019.03.002","article-title":"Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells","volume":"73","author":"Guenther","year":"2019","journal-title":"Exp Hematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.smim.2021.101516","article-title":"G-CSF - A double edge sword in neutrophil mediated immunity","volume":"54","author":"Martin","year":"2021","journal-title":"Semin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e872","DOI":"10.1097\/HS9.0000000000000872","article-title":"The european guidelines on diagnosis and management of neutropenia in adults and children: A consensus between the european hematology association and the euNet-INNOCHRON COST action","volume":"7","author":"Fioredda","year":"2023","journal-title":"Hemasphere"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/hem3.70113","article-title":"European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action based on a systematic evidence review","volume":"9","author":"Fioredda","year":"2025","journal-title":"Hemasphere"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29599","article-title":"Diagnosis and management of neutropenia in children: The approach of the Study Group on Neutropenia and Marrow Failure Syndromes of the Pediatric Italian Hemato-Oncology Association (Associazione Italiana Emato-Oncologia Pediatrica - AIEOP)","volume":"69","author":"Fioredda","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/imr.12719","article-title":"WHIM syndrome: Immunopathogenesis, treatment and cure strategies","volume":"287","author":"McDermott","year":"2019","journal-title":"Immunol Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-019-00665-w","article-title":"WHIM syndrome: from pathogenesis towards personalized medicine and cure","volume":"39","author":"Heusinkveld","year":"2019","journal-title":"J Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-368084","article-title":"The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome","volume":"118","author":"McDermott","year":"2011","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527226","article-title":"A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor","volume":"123","author":"McDermott","year":"2014","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the treatment of WHIM syndrome","volume":"380","author":"McDermott","year":"2019","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1808575","article-title":"A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome","volume":"144","author":"Badolato","year":"2024","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12935-022-02677-w","article-title":"Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets","volume":"22","author":"Asgharian","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.002","article-title":"Beyond the bench: Revitalizing ataluren development for rare genetic disorders","volume":"33","author":"Bezzerri","year":"2025","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25025","article-title":"Ataluren-driven restoration of Shwachman-Bodian-Diamond syndrome protein function in Shwachman-Diamond syndrome bone marrow cells","volume":"93","author":"Bezzerri","year":"2018","journal-title":"Am J Hematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134672","article-title":"Nonsense suppression therapy: new hypothesis for the treatment of inherited bone marrow failure syndromes","volume":"21","author":"Bezzerri","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040886","article-title":"Novel translational read-through-inducing drugs as a therapeutic option for shwachman-diamond syndrome","volume":"10","author":"Bezzerri","year":"2022","journal-title":"Biomedicines"},{"key":"B55","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41420-025-02571-0","article-title":"Development of translational read-through-inducing drugs as novel therapeutic options for patients with Fanconi anemia","volume":"11","author":"Hristodor","year":"2025","journal-title":"Cell Death Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-748129","article-title":"Metformin: treating the cause of Fanconi anemia","volume":"128","author":"Crossan","year":"2016","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006490","article-title":"Metformin for treatment of cytopenias in children and young adults with Fanconi anemia","volume":"6","author":"Pollard","year":"2022","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683490","article-title":"Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012403","article-title":"Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin","volume":"8","author":"Kaczor","year":"2024","journal-title":"Blood Adv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128581","article-title":"The paradox of autoimmunity and autoinflammation in inherited neutrophil disorders - in search of common patterns","volume":"14","author":"Krzyzanowski","year":"2023","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2024.1339317","article-title":"Unlocking longevity: the role of telomeres and its targeting interventions","volume":"5","author":"Schellnegger","year":"2024","journal-title":"Front Aging"},{"key":"B62","doi-asserted-by":"publisher","first-page":"123904","DOI":"10.1016\/j.lfs.2025.123904","article-title":"Telomere-targeted medicine: Bridging molecular mechanisms and clinical applications in age-related diseases","volume":"379","author":"Niazi","year":"2025","journal-title":"Life Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3184","article-title":"Inhibition of telomerase RNA decay rescues telomerase deficiency caused by dyskerin or PARN defects","volume":"23","author":"Shukla","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87547","article-title":"Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease","volume":"126","author":"Boyraz","year":"2016","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-885368","article-title":"Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita","volume":"133","author":"Fok","year":"2019","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001848","article-title":"Chemical inhibition of PAPD5\/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita","volume":"4","author":"Shukla","year":"2020","journal-title":"Blood Adv"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.041","article-title":"Presence of hypogammaglobulinemia and abnormal antibody responses in GATA2 deficiency","volume":"134","author":"Chou","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865773","article-title":"GATA 2 deficiency: focus on immune system impairment","volume":"13","author":"Fabozzi","year":"2022","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24046","article-title":"Immune status of patients with inherited bone marrow failure syndromes","volume":"90","author":"Giri","year":"2015","journal-title":"Am J Hematol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"109837","DOI":"10.1016\/j.clim.2023.109837","article-title":"Telomere biology disorders may manifest as common variable immunodeficiency (CVID)","volume":"257","author":"Rolles","year":"2023","journal-title":"Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017717","article-title":"Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management","volume":"145","author":"Sahoo","year":"2025","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09250.x","article-title":"Etanercept treatment in Fanconi anaemia; combined US and Italian experience","volume":"158","author":"Mehta","year":"2012","journal-title":"Br J Haematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.64","article-title":"Autophagy: Inflammatory pathology of Fanconi anaemia","volume":"17","author":"Minton","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.60","article-title":"Inflammation: Inflammatory pathology of Fanconi anaemia","volume":"16","author":"Minton","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01949-2","article-title":"Activation of distinct inflammatory pathways in subgroups of LR-MDS","volume":"37","author":"Schneider","year":"2023","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.05.007","article-title":"Where there\u2019s smoke, there\u2019s fire: inflammation drives MDS","volume":"41","author":"Datar","year":"2020","journal-title":"Trends Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431437","article-title":"Dietary L-leucine improves the anemia in a mouse model for Diamond-Blackfan anemia","volume":"120","author":"Jaako","year":"2012","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13069","article-title":"L-Leucine improves the anaemia in models of Diamond Blackfan anaemia and the 5q- syndrome in a TP53-independent way","volume":"167","author":"Narla","year":"2014","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-382986","article-title":"L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway","volume":"120","author":"Payne","year":"2012","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28748","article-title":"L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I\/II study from the Diamond-Blackfan Anemia Registry","volume":"67","author":"Vlachos","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11498","article-title":"Successful treatment of a Diamond-Blackfan anemia patient with amino acid leucine","volume":"92","author":"Pospisilova","year":"2007","journal-title":"Haematologica"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443978","article-title":"L-Leucine alleviates Diamond-Blackfan anemia","volume":"120","author":"Kamimae-Lanning","year":"2012","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"key":"B84","volume-title":"Fanconi anemia clinical care guidelines.: fanconi anemia research fund","author":"Sroka","year":"2020"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015053","article-title":"Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia","volume":"9","author":"Mehta","year":"2025","journal-title":"Blood Adv"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70007","article-title":"Eltrombopag for bone marrow failure in fanconi anemia: results from the phase II clinical trial FANCREV","volume":"115","author":"Iriondo","year":"2025","journal-title":"Eur J Haematol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1625751","article-title":"Case Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemia","volume":"13","author":"Zubicaray","year":"2025","journal-title":"Front Pediatr"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.05.003","article-title":"Small molecules restore telomeres in patient stem cells","volume":"41","author":"Brenner","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.stem.2020.03.016","article-title":"Small-molecule PAPD5 inhibitors restore telomerase activity in patient stem cells","volume":"26","author":"Nagpal","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-024-02091-1","article-title":"A revolutionary oral HBV treatment candidate as innovative therapeutic approach warranting clinical trials","volume":"59","author":"Matsui","year":"2024","journal-title":"J Gastroenterol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"8189","DOI":"10.1038\/s41467-025-63137-3","article-title":"Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series","volume":"16","author":"Bezzerri","year":"2025","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/bjh.19134","article-title":"Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells","volume":"204","author":"Cipolli","year":"2024","journal-title":"Br J Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164918","article-title":"A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome","volume":"133","author":"McDermott","year":"2023","journal-title":"J Clin Invest"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173549","article-title":"Mavorixafor for patients with chronic neutropenic disorders treated with G-CSF: preliminary response data and G-CSF dose reduction in an ongoing phase 2, open-label, multicenter study support reduction in G-CSF dosing","author":"Warren","year":"2023","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280856","article-title":"Treatment of inherited thrombocytopenias","volume":"107","author":"Balduini","year":"2022","journal-title":"Haematologica"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-304725","article-title":"Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations","volume":"116","author":"Pecci","year":"2010","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-01-0005","article-title":"Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation","volume":"107","author":"Pecci","year":"2012","journal-title":"Thromb Haemost"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25500","article-title":"Eltrombopag in preparation for surgery in patients with severe MYH9-related thrombocytopenia","volume":"94","author":"Zaninetti","year":"2019","journal-title":"Am J Hematol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26692","article-title":"Eltrombopag use in a patient with Wiskott-Aldrich syndrome","volume":"64","author":"Gabelli","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.223966","article-title":"Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial","volume":"105","author":"Zaninetti","year":"2020","journal-title":"Haematologica"},{"key":"B101","doi-asserted-by":"publisher","first-page":"63","DOI":"10.15252\/emmm.201708168","article-title":"Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim","volume":"10","author":"Pecci","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41467-021-21588-4","article-title":"Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome","volume":"12","author":"Kennedy","year":"2021","journal-title":"Nat Commun"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017739","article-title":"Predisposition to myeloid Malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances","volume":"141","author":"Reilly","year":"2023","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2017.09.002","article-title":"Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome","volume":"67","author":"Warren","year":"2018","journal-title":"Adv Biol Regul"},{"key":"B105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.drudis.2012.07.009","article-title":"Drug repurposing in pediatrics and pediatric hematology oncology","volume":"18","author":"Blatt","year":"2013","journal-title":"Drug Discov Today"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.stem.2021.02.008","article-title":"HectD1 controls hematopoietic stem cell regeneration by coordinating ribosome assembly and protein synthesis","volume":"28","author":"Lv","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019986","article-title":"Emerging genetic technologies informing personalized medicine in Shwachman-Diamond syndrome and other inherited BMF disorders","volume":"144","author":"Cull","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:59:00Z","timestamp":1772607540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1773574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2026.1773574"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1773574","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"article-number":"1773574"}}